Reported 11 months ago
In response to the impact on large-volume infusion drug supply due to the suspension of production at the Yung Fong Chemical Industrial Co., Ltd.'s New Taipei factory, the Taiwanese Food and Drug Administration has been taking measures since May 113. FDA Director Wu Xiumei claimed on the 19th that there was no shortage on the medical end, but evidence presented by Dr. Su Yifeng disputes this, stating that he was blocked from prescribing saline solution due to the system. Su criticized the Ministry of Health for allegedly lying when it claimed there were no shortages in medical facilities. The FDA website, however, stated that efforts have been made to meet clinical demands and stabilize Taiwan's infusion supply.
Source: YAHOO